Makary seeks to limit industry’s role in FDA advisory panels

FDA fires most negotiators for pharma user fee talks, sources say

Exclusive-FDA fires most negotiators for pharma user fee talks, sources say

Elections can change something. The new head of the U.S. FDA pushes the representatives of Big Pharma out of the advisory bodies of the agency. Does the practice of turning Böcke into gardeners finally come to an end? For many years, the common practice of bringing Big Pharma representatives into important bodies of the U.S. Food and Drug Administration FDA has been sharply criticized.

FDA To Remove Pharma Reps from Advisory Panels

The Food and Drug Administration (FDA) will remove representatives of pharmaceutical companies from its advisory committees

FDA Removing Pharmaceutical Representatives From Advisory Panels

The Food and Drug Administration (FDA) is removing pharmaceutical company representatives from advisory committees in a bid to limit industry influence. Dr. Marty Makary, the FDA’s new commissioner, issued a directive that eliminates the role of pharmaceutical representative. “Industry employees are welcome to attend FDA advisory committee meetings, along with the rest of the American public, but having industry employees serve as official membe…

FDA Announces New Policy on Advisory Committee Members

The policy announced by Commissioner Martin A. Makary, MD, will not preclude employees of regulated companies from presenting their views to committees, and rare exceptions will be allowed.

New FDA head says no more pharma on advisory committees

New FDA head says no more pharma on advisory committees Jonah.Comstock Fri, 18/04/2025 - 17:43 Bookmark this